Int J Thyroidol.  2024 May;17(1):1-20. 10.11106/ijt.2024.17.1.1.

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Overview and Summary 2024

• Park YJ
• Lee EK
• Song YS
• Koo BS
• Kwon H
• Kim K
• Kim M
• Kim BH
• Kim WG
• Kim WB
• Kim WW
• Kim JH
• Kim HK
• Na HY
• Moon SJ
• Moon JE
• Park S
• Park JO
• Bang JI
• Back K
• Seo Y
• Shin DY
• Shin SJ
• Ahn HY
• Oh SW
• Woo SH
• Won HR
• Ryu CH
• Yoon JH
• Yi KH
• Lee MK
• Lee SW
• Lee SE
• Lee S
• Lee YA
• Lee JH
• Lee JY
• Lee J
• Lee CR
• Lim DJ
• Lim JY
• Jeon YK
• Jung KY
• Chong A
• Chung YJ
• Jung CK
• Jo K
• Cho YY
• Hong AR
• Hong CM
• Kang HC
• Kim SW
• Chung WY
• Park DJ
• Na DG
• Korean Thyroid Association Guideline Committee on the Managements of Thyroid Nodule and Cancer

• KMID: 2556502
• DOI: http://doi.org/10.11106/ijt.2024.17.1.1

Abstract

Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.

Keyword

Thyroid cancer; Guideline; Differentiated thyroid cancer; Korean Thyroid Association

Reference

References

1. Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. 2023; Thyroid cancer. Lancet. 401(10387):1531–44. DOI: 10.1016/S0140-6736(23)00020-X. PMID: 37023783.

2. Nabhan F, Dedhia PH, Ringel MD. 2021; Thyroid cancer, recent advances in diagnosis and therapy. Int J Cancer. 149(5):984–92. DOI: 10.1002/ijc.33690. PMID: 34013533.

3. Kitahara CM, Schneider AB. 2022; Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev. 31(7):1284–97. DOI: 10.1158/1055-9965.EPI-21-1440. PMID: 35775227. PMCID: PMC9473679.

4. Kim WB, Kim TY, Kwon HS, Moon WJ, Lee JB, Choi YS, et al. 2007; Management guidelines for patients with thyroid nodules and thyroid cancer. J Korean Endocr Soc. 22(3):157–87. DOI: 10.3803/jkes.2007.22.3.157.

5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI: 10.1089/thy.2015.0020. PMID: 26462967. PMCID: PMC4739132.

6. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS, et al. 2010; Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. J Korean Thyroid Assoc. 3(2):65–96.

7. Yi KH. 2016; The revised 2016 Korean Thyroid Association guidelines for thyroid nodules and cancers: differences from the 2015 American Thyroid Association guidelines. Endocrinol Metab (Seoul). 31(3):373–8. DOI: 10.3803/EnM.2016.31.3.373. PMID: 27704738. PMCID: PMC5053047.

8. Yi KH, Lee EK, Kang HC, Koh Y, Kim SW, Kim IJ, et al. 2016; 2016 revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 9(2):59–126. DOI: 10.11106/ijt.2016.9.2.59.

9. Park YJ, Lee EK, Song YS, Kang SH, Koo BS, Kim SW, et al. 2023; 2023 Korean Thyroid Association management guidelines for patients with thyroid nodules. Int J Thyroidol. 16(1):1–31. DOI: 10.11106/ijt.2023.16.1.1.

10. Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. 2023; The 2023 Bethesda system for reporting thyroid cytopathology. J Am Soc Cytopathol. 12(5):319–25. DOI: 10.1016/j.jasc.2023.05.005. PMID: 37438235.

11. Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. 2023; The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid. 33(9):1039–44. DOI: 10.1089/thy.2023.0141. PMID: 37427847.

12. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021; 2021 Korean Thyroid Imaging Reporting and Data System and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol. 22(12):2094–123. DOI: 10.3348/kjr.2021.0713. PMID: 34719893. PMCID: PMC8628155.

13. Jung CK, Baek JH, Na DG, Oh YL, Yi KH, Kang HC. 2020; 2019 practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association. J Pathol Transl Med. 54(1):64–86. DOI: 10.4132/jptm.2019.12.04. PMID: 31964112. PMCID: PMC6986975.

14. Park JO, Kim JH, Joo YH, Kim SY, Kim GJ, Kim HB, et al. 2023; Guideline for the surgical management of locally invasive differentiated thyroid cancer from the Korean Society of Head and Neck Surgery. Clin Exp Otorhinolaryngol. 16(1):1–19. DOI: 10.21053/ceo.2022.01732. PMID: 36634669. PMCID: PMC9985989.

15. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. 2011; Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 21(2):125–34. DOI: 10.1089/thy.2010.0021. PMID: 21186939. PMCID: PMC3025182.

16. Mazzaferri EL, Jhiang SM. 1994; Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97(5):418–28. DOI: 10.1016/0002-9343(94)90321-2. PMID: 7977430.

17. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. 1998; A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 83(12):2638–48. DOI: 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1.

18. Mazzaferri EL. 1999; An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 9(5):421–7. DOI: 10.1089/thy.1999.9.421. PMID: 10365671.

19. Mazzaferri EL. 2000; Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 6(6):469–76. DOI: 10.4158/EP.6.6.469. PMID: 11155222.

20. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. 1998; Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 8(9):737–44. DOI: 10.1089/thy.1998.8.737. PMID: 9777742.

21. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. 1993; Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 114(6):1050–7. discussion 7–8.

22. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. 2003; Clinical course of thyroid carcinoma after neck dissection. Laryngoscope. 113(12):2102–7. DOI: 10.1097/00005537-200312000-00008. PMID: 14660910.

23. Wang TS, Dubner S, Sznyter LA, Heller KS. 2004; Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 130(1):110–3. DOI: 10.1001/archotol.130.1.110. PMID: 14732779.

24. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY. 1998; Use of radioactive iodine for thyroid remnant ablation in well- differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol. 21(1):77–81. DOI: 10.1097/00000421-199802000-00018. PMID: 9499265.

25. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. 1997; A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 79(12):2414–23. DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2414::AID-CNCR18>3.0.CO;2-U.

26. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. 2002; Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 26(8):879–85. DOI: 10.1007/s00268-002-6612-1. PMID: 12016468.

27. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. 1998; The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 228(3):320–30. DOI: 10.1097/00000658-199809000-00005. PMID: 9742915. PMCID: PMC1191485.

28. Loyo M, Tufano RP, Gourin CG. 2013; National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope. 123(8):2056–63. DOI: 10.1002/lary.23923. PMID: 23737403.

29. Stavrakis AI, Ituarte PH, Ko CY, Yeh MW. 2007; Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 142(6):887–99. discussionDOI: 10.1016/j.surg.2007.09.003. PMID: 18063073.

30. Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, et al. 2005; Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 12(2):273–80. DOI: 10.1677/erc.1.00892. PMID: 15947102.

31. Kim S, Wei JP, Braveman JM, Brams DM. 2004; Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg. 139(4):390–4. discussion 3–4. DOI: 10.1001/archsurg.139.4.390. PMID: 15078706.

32. Bogdanovski AK, Sturgeon C, James BC. 2023; Financial toxicity in thyroid cancer survivors. Curr Opin Endocrinol Diabetes Obes. 30(5):238–43. DOI: 10.1097/MED.0000000000000826. PMID: 37470486.

33. Mongelli MN, Giri S, Peipert BJ, Helenowski IB, Yount SE, Sturgeon C. 2020; Financial burden and quality of life among thyroid cancer survivors. Surgery. 167(3):631–7. DOI: 10.1016/j.surg.2019.11.014. PMID: 31862171.

34. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, et al. 2004; Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging. 48(1):12–9.

35. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. 1996; Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 37(4):598–605.

36. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. 2001; Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 86(4):1568–73. DOI: 10.1210/jcem.86.4.7390. PMID: 11297585.

37. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, et al. 2002; Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy? Clin Endocrinol (Oxf). 56(3):377–82. DOI: 10.1046/j.1365-2265.2002.01482.x. PMID: 11940050.

38. Chiu AC, Delpassand ES, Sherman SI. 1997; Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 82(11):3637–42. DOI: 10.1210/jcem.82.11.4386. PMID: 9360519.

39. Lin JD, Chao TC, Chou SC, Hsueh C. 2004; Papillary thyroid carcinomas with lung metastases. Thyroid. 14(12):1091–6. DOI: 10.1089/thy.2004.14.1091. PMID: 15650364.

40. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. 2003; Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 197(2):191–7. DOI: 10.1016/S1072-7515(03)00332-6. PMID: 12892796.

41. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, et al. 2000; Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 10(3):261–8. DOI: 10.1089/thy.2000.10.261. PMID: 10779141.

42. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. 1995; Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 80(7):2041–5. DOI: 10.1210/jcem.80.7.7608252. PMID: 7608252.

43. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, et al. 2003; Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 88(7):3184–9. DOI: 10.1210/jc.2003-030231. PMID: 12843163.

44. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. 2003; Is there a role for radiation therapy in the management of Hurthle cell carcinoma? Int J Radiat Oncol Biol Phys. 56(4):1067–72. DOI: 10.1016/S0360-3016(03)00199-8. PMID: 12829143.

45. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, et al. 2003; Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol. 82(1):10–8. DOI: 10.1002/jso.10189. PMID: 12501164.

46. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. 2001; Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer. 84(12):1586–90. DOI: 10.1054/bjoc.2001.1832. PMID: 11401309. PMCID: PMC2363684.

47. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. 1999; Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 84(11):4043–9. DOI: 10.1210/jcem.84.11.6115. PMID: 10566647.

48. Lee YA, Jung HW, Kim HY, Choi H, Kim HY, Hah JH, et al. 2015; Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab. 100(4):1619–29. DOI: 10.1210/jc.2014-3647. PMID: 25632969.

49. Redlich A, Luster M, Lorenz K, Lessel L, Rohrer TR, Schmid KW, et al. 2022; Age, American Thyroid Association risk group, and response to therapy are prognostic factors in children with differentiated thyroid cancer. J Clin Endocrinol Metab. 107(1):e165–e77. DOI: 10.1210/clinem/dgab622. PMID: 34415989.

50. Rangel-Pozzo A, Sisdelli L, Cordioli MIV, Vaisman F, Caria P, Mai S, et al. 2020; Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations. Cancers (Basel). 12(11):3146. DOI: 10.3390/cancers12113146. PMID: 33120984. PMCID: PMC7693829.

51. van de Berg DJ, Kuijpers AMJ, Engelsman AF, Drukker CA, van Santen HM, Terwisscha van Scheltinga S, et al. 2022; Long-term oncological outcomes of papillary thyroid cancer and follicular thyroid cancer in children: a nationwide population- based study. Front Endocrinol (Lausanne). 13:899506. DOI: 10.3389/fendo.2022.899506. PMID: 35600573. PMCID: PMC9114695.

52. Lee YA, Im SW, Jung KC, Chung EJ, Shin CH, Kim JI, et al. 2020; Predominant DICER1 pathogenic variants in pediatric follicular thyroid carcinomas. Thyroid. 30(8):1120–31. DOI: 10.1089/thy.2019.0233. PMID: 32228164.